1. bookVolume 24 (2016): Issue 2 (June 2016)
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

The grade of neoangiogenesis and the bone marrow blast count predict leukemic transformation-free survival in myelodysplastic syndromes

Published Online: 28 Jun 2016
Page range: 228 - 231
Received: 17 Jan 2016
Accepted: 19 Apr 2016
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English

1. Fenaux P, Haase D, Sanz GF, Santini V, Buske C. Clinical practice guidelines Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25(Suppl 3):57-69. DOI: 10.1093/annonc/mdu180.10.1093/annonc/mdu180Search in Google Scholar

2. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised International Prognostic Scoring System for Myelodisplastic Syndromes. Blood. 2012 Sep; 120(12):2454-65. DOI: 10.1182/blood-2012-03-420489.10.1182/blood-2012-03-420489Search in Google Scholar

3. Bănescu C, Benedek I, Duicu C, Demian S, Voidăzan S. Cytogenetic findings and their prognostic impact in myelodysplastic syndrome patientes. Revista Română de Medicină de Laborator. 2011 Iun;2(19):139-47.Search in Google Scholar

4. Duarte FB, Goncalves RP, Barbosa MC, Rocha Filho FD, de Jesus dos Santos TE, Nogueira dos Santos T, et al. Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome. Rev Bras Hemathol Hemother. 2014 Apr;36(3):196-201. DOI: 10.1016/j.bjhh.2014.03.007.10.1016/j.bjhh.2014.03.007Search in Google Scholar

5. Nolte F, Hofmann WK. Molecular mechanisms involved in the progression of myelodysplastic syndrome. Future Oncol. 2010 Mar;6(3):445-55. DOI: 10.2217/fon.09.175.10.2217/fon.09.175Search in Google Scholar

6. Bejar RK, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutation in Myelodysplastic Syndromes. N Engl J Med. 2011 Iun; 364: 2496-506.10.1056/NEJMoa1013343Search in Google Scholar

7. Porwit A, Saft L. The AML-MDS interface-leukemic transformation in myelodysplastic syndromes. J Hematop. 2011 May;4(2):69-79. DOI: 10.1007/ s12308-011-0088-6.10.1007/s12308-011-0088-6Search in Google Scholar

8. Savic A, Cemerikic-Martinovic V, Dovat S, Rajic N, Urosevic I, Sekulic B, et al. “Angiogenesis and survival in patients with myelodysplastic syndrome”. Pathol Oncol Res. 2012 Jul;18(3):681-90. DOI: 10.1007/ s12253-012-9495-y.10.1007/s12253-012-9495-ySearch in Google Scholar

9. Cheng CL, Hou HA, Jhuang JY, Lin CW, Chen CY, Tang JL, et al. High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes. Br J Cancer. 2011 Aug;105(7);975-82. DOI: 10.1038/ bjc.2011.340.10.1038/bjc.2011.340Search in Google Scholar

10. Ribatti D, Polimeno G, Vacca G, Marzullo A, Crivellato E, Nico B, et al. Correlation of bone marrow angiogenesis and mast cells with tryptase activity in myelodysplastic syndromes. Leukemia. 2002 Sep;16(9):1680-4. DOI: 10.1038/sj.leu.2402586.10.1038/sj.leu.2402586Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo